Future chemotherapy and radiotherapy options in head and neck cancer

Expert Review of Anticancer Therapy

Volumn 6, Issue 3, 2006, Pages 395-403

  Merlano, Marco ^a   Mattiot, Valentina Polla ^a  

^a S CROCE E CARLE HOSPITAL   (Italy)

Author keywords

Advanced head and neck cancer; Chemoradiation; Current and future opportunities; Expertise; Mechanism of action; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BLEOMYCIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; HYDROXYUREA; METHOTREXATE; PACLITAXEL; PROTEIN TYROSINE KINASE; TIRAPAZAMINE; VINBLASTINE;

ADVANCED CANCER; ANGIOGENESIS; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL HYPOXIA; CLINICAL TRIAL; DRUG FATALITY; DRUG TARGETING; FIBROSIS; HEAD AND NECK CANCER; HEAD AND NECK SURGERY; HIGH RISK PATIENT; HUMAN; INHIBITION KINETICS; METASTASIS POTENTIAL; NECROSIS; OVERALL SURVIVAL; PATIENT COMPLIANCE; POSTOPERATIVE CARE; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; REVIEW; STOMATITIS; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT WITHDRAWAL; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CONTROLLED CLINICAL TRIAL; HEAD AND NECK TUMOR; MULTIMODALITY CANCER THERAPY; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; NEOADJUVANT THERAPY; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS;

EID: 33644892493     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.3.395     Document Type: Review

References (54)

1. Pignon JP, Bourhis J, Domenge C et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC collaborative group. Meta-analysis of chemotherapy in head and neck cancer. Lancet 355, 949-955 (2000).
2. Merlano M, Marchetti G. Radiochemotherapy in head and neck cancer. Cancer Treat. Rev. 29, 291-296 (2003).
3. Hennequin C, Favadoun V. Biological basis for chemoradiotherapy interactions. Eur. J. Cancer 38, 223-230 (2002).
4. Adelstein DJ, Saxton JP, Lavertu P et al. A Phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III-IV squamous cell head and neck cancer: preliminary results. Head Neck 19, 567-751 (1997).
5. Merlano M, Rosso R, Sertoli MR et al. Sequential versus alternating chemotherapy and radiotherapy in stage III-IV squamous cell carcinoma of the head and neck: a Phase III study. J. Clin. Oncol. 6, 627-632 (1988).
6. Eisbruch A, Shewach DS, Bradford CR et al. Radiation concurrent with gemcitabine for locally advanced head and neck cancer; a Phase I trial and intracellular drug incorporation study. J. Clin. Oncol. 19, 792-799 (2001).
7. Koukourakis ML. Tumor angiogenesis and response to radiotherapy. Anticancer Res. 21, 4285-4300 (2001).
8. Brockstein BE, Haraf DJ, Kies M et al. Distant metastases after chemoradiotherapy for head and neck cancer. Proc. Am. Soc. Clin. Oncol. 19, 414a (2000) (Abstract 1635).
9. Monnerat C, Faivre S, Temam S et al. End points for new agents in induction chemotherapy for locally advanced head and neck cancer. Ann. Oncol. 13, 995-1006 (2002).
10. Haffty GB. Concurrent chemoradiation in the treatment of head and neck cancer. Hemathol. Oncol. Clin. North. Am. 13, 719-742 (1999).
11. Merlano M. Alternating chemotherapy and radiotherapy in locally advanced head and neck cancer: an alternative? Oncologist 11(2), (2006) (In press).
12. Browman GP, Cripps C, Hodson DI et al. Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J. Clin. Oncol. 12, 2648-2653 (1994).
13. Fu KK, Pajak TF, Trotti A et al. A Radiation Therapy Oncology Group (RTOG) Phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinoma: first report of RTOG 9003. Int. J. Radiat. Oncol. Biol. Phys. 48, 7-16 (2000).
14. Merlano M, Corvò R, Margarino G et al. Combined chemotherapy and radiation therapy in advanced inoperable squamous cell carcinoma of the head and neck. The final report of a randomized trial. Cancer 67, 915-921 (1991).
15. SECOG participants. A randomized trial of combined multidrug chemotherapy and radiotherapy in advanced squamous cell carcinoma of the head and neck. Eur. J. Surg. Oncol. 2, 289-295 (1986).
16. Merlano M, Vitale V, Rosso R et al. Treatment of advanced squamous cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N. Engl. J. Med. 327, 1115-1121 (1992).
17. Adelstein DJ, Li Y, Adams GL et al. An Intergroup Phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J. Clin. Oncol. 21, 92-98 (2003).
18. Al-Sarraf M, Le Blanc M, Shanker Giri PG et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J. Clin. Oncol. 16, 1310-1317 (1998).
19. Brizel DM, Albers ME, Fisher SR et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 338, 1798-1804 (1998).
20. Wendt TG, Grabenbauer GG, Rodel CM et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J. Clin. Oncol. 16, 1318-1324 (1998).
21. Huguenin P, Beer KT, Allal A et al. Concomitant cisplatin significantly improves loco-regional control in advanced head and neck cancer treated with hyperfractionated radiotherapy. J. Clin. Oncol. 22, 4665-4673 (2004).
22. Jeremic B, Shibamoto Y, Milicic B et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J. Clin. Oncol. 18, 1458-1464 (2000).
23. Corvo' R, Benasso M, Sanguineti G et al. Alternating chemoradiotherapy cersus partly accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck. Cancer 92, 2856-2867 (2001).
24. Bernier J, Domenge C, Ozshein M et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 350, 1945-1952 (2004).
25. Cooper JS, Pajak TF, Forastiere AA et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous cell carcinoma of the head and neck. N. Engl. J. Med. 350, 1937-1944 (2004).
26. Merlano M, Russi E, Numico G et al. Paclitaxel, cisplatin 5-fluorouracil and radiotherapy in the management of advanced squamous cell carcinoma of the head and neck. A Phase II study. Radiother. Oncol. 75, 193-196 (2005).
27. Benasso M, Corvo' R, Ponzanelli A et al. Alternating gemcitabine and cisplatin with gemcitabine and radiation in stage IV squamous cell carcinoma of the head and neck. Ann. Oncol. 15, 646-652 (2004).
28. Garden AS, Harris J, Vokes EE et al. Preliminary results of Radiation Oncology Group 97-03: a randomized Phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J. Clin. Oncol. 22, 2856-2864 (2004).
29. Rosen F, Haraf DJ, Kies MS et al. Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluoruracil, hydrossiurea and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin. Cancer Res. 9, 1689-1697 (2003).
30. Merlano M, Colantonio I, Numico G et al. Phase II randomized trial of neoadjuvant chemotherapy (NACT) followed by chemoradiation vs chemoradiation alone in locally advanced head and neck cancer (HNC): a feasibility study. Ann. Oncol. 15(2), (2004) (Abstract B36).
31. Machtay M, Rosenthal DI, Hershock D et al. Organ preservation therapy using induction plus concurrent chemoradiation for advanced respectable oropharyngeal carcinoma: a University of Pensylvania Phase II trial. J. Clin. Oncol. 20, 3964-3971 (2002).
32. Psirry A, Kwong M, DiStasio S et al. Cisplatin, fluorouracil and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long term follow-up. J. Clin. Oncol. 22, 3061-3069 (2004).
33. Kies MS, Haraf DJ, Athanasiadis I et al. Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival. J. Clin. Oncol. 16, 2715-2721 (1998).
34. Forastiere A, Koch W, Trotti A et al. Head and neck cancer. N. Engl. J. Med. 345, 1890-1900 (2001).
35. Adelstein DJ, Saxton JP, Lavertu P et al. Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer, with hyperfractionated radiation and concurrent chemotherapy. J. Clin. Oncol. 20, 1405-1410 (2002).
36. Benasso M, Bonelli L, Numico G et al. Treatment with cisplatin and fluoruracil alternating with radiation favour prognosis of inoperable squamous cell carcinoma of the head and neck: a multivariate analysis on 273 patients. Ann. Oncol. 8, 773-779 (1997).
37. Benasso M, Lionetto R, Corvò R et al. Impact of the treating institution on the survival of patients with head and neck cancer treated with concomitant alternating chemotherapy and radiotherapy. Eur. J. Cancer 39, 1895-1898 (2003).
38. Taylor SG 4th, Murthy AK, Vannetzell JM. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J. Clin. Oncol. 12, 385-395 (1994).
39. Liang K, Ang KK, Milas L et al. The growth factor receptor mediates radioresistance. Int. J. Radiat. Oncol. Biol. Phys. 57, 246-254 (2003).
40. Mendelshon J. Targeting the epidermal growth factor receptor for cancer therapy. J. Clin. Oncol. 20, 1S-13S (2002).
41. Ochs J. Rationale and clinical basis for combining gefitinib (IRESSA) with radiation therapy in solid tumors. Int. J. Radiat. Oncol. Biol. Phys. 58, 941-949 (2004).
42. Huang S-M, Harari PM. Modulation of RT response after EGFr blockade in SCC: inhibition of damage repair, cell cycle kinetic and tumor angiogenesis. Clin. Cancer Res. 6, 2166-2174 (2000).
43. Harari P, Huang S-M. Head and neck cancer as a clinical model for molecular targeting of therapy combining EGFR blockade with radiation. Int. J. Rad. Oncol. 49, 427-433 (2001).
44. Magné N, Fischel J-L, Tiffon C et al. Molecular mechanisms underlying the interaction between ZD 1839 (Iressa) and cisplatin /5-fluorouracil. Br. J. Cancer 89, 585-592 (2003).
45. Harari PM. Epidermal growth factor receptor inhibitions strategies in oncology. Endocr: Relat. Cancer 11, 689-708 (2004).
46. Baselga J, Trigo JM, Boughis J et al. Phase II multicenter study of the antiepideram growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol. 23, 5668-5677 (2005).
47. Johnson DH, Feherenbacher L, Novotny WF et al. Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 22, 2184-2191 (2004).
48. Rosemberg A, Knox S. Radiation sensitization with redox modulators: a promising approach. Int. J. Radiat. Oncol. Biol. Phys. 64, 343-354 (2006).
49. Rischin D, Peters L, Fisher R et al. Tirapazamine, cisplatin and radiation vs fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized Phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J. Clin. Oncol. 23, 79-87 (2005).
50. Bonner JA, Harari P, Giralt J et al. Phase III study of high dose radiation with or without cetuximab in the treatment of locoregionally advanced squamous cell cancer of the head and neck (SCC-HN). Proceedings of the American Society of Clinical Oncology Annual Meeting. New Orleans, LA, USA, 5-8 June 2004 (Abstract 5507).
51. Pfister DG, Aliff TB, Kraus DH et al. Concurrent cetuximab, cisplatin and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: preliminary evaluation of a new combined modality paradigm. Proceedings of the American Society of Clinical Oncology Annual Meeting. New Orleans, LA, USA, 5-8 June 2004 (Abstract 1993).
52. Su YB, Kraus DH, Zelefsky MJ et al. Concurrent cetuximab, cisplatin and radiotherapy (RT) for loco-regionally advanced squamous cell carcinoma of the head and neck (SCCHN): updated results of a novel combined modality paradigm. Proceedings of the American Society of Clinical Oncology Annual Meeting. New Orleans, LA, USA, 5-8 June 2004 (Abstract 5529).
53. Merlano M, Colantonio I, Numico G et al. Fast tumor re-growth of head and neck cancer (HNC) after compassionate treatment (CTr) with re-irradiation, carboplatin and concurrent cetuximab. ESMO Scientific and Educational Conference. Budapest, Hungary, 2-5 June 2005 (Abstract 102P).
54. Merlano M, Colantonio I, Numico G et al. Alternating radiotherapy and chemotherapy plus cetuximab in advanced head and neck cancer (HNC): the AlteRCC Phase I-II trial. Ann. Oncol. 16(7), (2005) (Abstract B20).